June 10, 2025 10:49 AM EDT

Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues

ENDPOINTS

Plus, news about AriBio, Arcera, Molecular Partners, Valneva, MacroGenics, Sagard Healthcare Partners, Quell Therapeutics, AstraZeneca, Guardian Bio, Lucy Therapeutics, Argenica, and Gilead’s Tmunity:

Insmed’s stock …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues

ENDPOINTS

Sign up to read this article for free.

Another round of consolidation is coming, FDA commissioner tells staff

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

McKesson leads the charge in revolutionizing precision oncology in community practices

In­smed’s stock ral­lies on PAH da­ta; Uni­cy­cive aims to re­solve CD­MO is­sues

ENDPOINTS

Sign up to read this article for free.

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues

Another round of consolidation is coming, FDA commissioner tells staff

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

McKesson leads the charge in revolutionizing precision oncology in community practices